CYNATA THERAPEUTICS LIMITED (CYP)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
CYP - CYNATA THERAPEUTICS LIMITED
FNArena Sector :
NONE
Year End: June
GICS Industry Group : NONE
Debt/EBITDA: N/A
Index:
FNArena Sector : NONE
Year End: June
GICS Industry Group : NONE
Debt/EBITDA: N/A
| LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
|---|---|---|---|
|
$0.20
20 Dec |
OPEN $0.18 |
HIGH $0.21 |
292,193 LOW $0.20 |
0.005FNARENA'S MARKET CONSENSUS FORECASTS
- No Record -
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
| Title | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| EPS Basic | xxx | xxx | xxx | xxx | xxx | -5.4 |
| DPS All | xxx | xxx | xxx | xxx | xxx | 0.0 |
| Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 0.0 M |
| Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 4.0 |
| Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | -10.0 M |
| Net Profit Margin | xxx | xxx | xxx | xxx | xxx | - |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
| Title | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | -81.37 % |
| Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | -81.37 % |
| Return on Assets | xxx | xxx | xxx | xxx | xxx | -71.18 % |
| Return on Equity | xxx | xxx | xxx | xxx | xxx | -81.37 % |
| Return on Total Capital | xxx | xxx | xxx | xxx | xxx | -104.76 % |
| Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | -10.0 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
| Title | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 0 M |
| Long Term Debt | xxx | xxx | xxx | xxx | xxx | 0 M |
| Total Debt | xxx | xxx | xxx | xxx | xxx | 0 M |
| Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | - |
| Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 6 M |
| Price To Book Value | xxx | xxx | xxx | xxx | xxx | 7.34 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
| Title | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Capex | xxx | xxx | xxx | xxx | xxx | 0.0 M |
| Capex % of Sales | xxx | xxx | xxx | xxx | xxx | - |
| Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 0 M |
| Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 12 M |
| Research & Development | xxx | xxx | xxx | xxx | xxx | 9 M |
| Investments - Total | xxx | xxx | xxx | xxx | xxx | 0 M |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
EXTRA COVERAGE
Display All Commentary
No. Of Recommendations
Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.
CYP STOCK CHART
FNArena News on CYP
| 1 |
ASX Biotechs Surfing The Covid StoryAug 10 2020 - Weekly Reports |
| 2 |
Oz Biotech Stocks Worth PursuingJun 17 2014 - Australia |
| 3 |
Cynata Strikes A Chord In Regenerative MedicineJun 03 2014 - Small Caps |